Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 CAD | -8.62% | -10.17% | +31.68% |
04-01 | CareRx Down 3% as Notes Ontario Government's Pause of Planned Fee Changes | MT |
04-01 | CareRx Brief: Notes Ontario Government's Pause of Planned Fee Changes | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 43.52 | 94.36 | 248.8 | 130.5 | 96.33 | 127.5 | - | - |
Enterprise Value (EV) 1 | 43.52 | 150.9 | 248.8 | 130.5 | 96.33 | 127.5 | 127.5 | 127.5 |
P/E ratio | - | -4.27 x | -8.75 x | -3.56 x | -17.9 x | 249 x | 12.2 x | 8.02 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 0.35 x | 0.58 x | 0.95 x | 0.34 x | 0.26 x | 0.34 x | 0.33 x | 0.31 x |
EV / Revenue | 0.35 x | 0.58 x | 0.95 x | 0.34 x | 0.26 x | 0.34 x | 0.33 x | 0.31 x |
EV / EBITDA | 3.43 x | 7.39 x | 10.9 x | 4.05 x | 3.36 x | 3.97 x | 3.25 x | 2.7 x |
EV / FCF | - | -70.7 x | 130 x | 15 x | 5.16 x | 7.87 x | - | - |
FCF Yield | - | -1.41% | 0.77% | 6.68% | 19.4% | 12.7% | - | - |
Price to Book | - | - | - | 2.03 x | - | - | - | - |
Nbr of stocks (in thousands) | 14,037 | 24,572 | 43,732 | 50,985 | 59,831 | 60,165 | - | - |
Reference price 2 | 3.100 | 3.840 | 5.690 | 2.560 | 1.610 | 2.120 | 2.120 | 2.120 |
Announcement Date | 26/03/20 | 10/03/21 | 17/03/22 | 09/03/23 | 07/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 124.6 | 162.2 | 262.6 | 381.7 | 370.7 | 369.9 | 387.6 | 409.7 |
EBITDA 1 | 12.69 | 12.78 | 22.87 | 32.27 | 28.67 | 32.13 | 39.19 | 47.25 |
EBIT | - | -12.32 | -3.307 | - | - | - | - | - |
Operating Margin | - | -7.6% | -1.26% | - | - | - | - | - |
Earnings before Tax (EBT) | - | -18.3 | -23.74 | -35.9 | - | - | - | - |
Net income 1 | - | -18.26 | -22.73 | -34.35 | -5.405 | -2.522 | -2.077 | - |
Net margin | - | -11.26% | -8.65% | -9% | -1.46% | -0.68% | -0.54% | - |
EPS 2 | - | -0.9000 | -0.6500 | -0.7200 | -0.0900 | 0.008500 | 0.1743 | 0.2645 |
Free Cash Flow 1 | - | -1.334 | 1.918 | 8.72 | 18.68 | 16.2 | - | - |
FCF margin | - | -0.82% | 0.73% | 2.28% | 5.04% | 4.38% | - | - |
FCF Conversion (EBITDA) | - | - | 8.39% | 27.02% | 65.15% | 50.42% | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 26/03/20 | 10/03/21 | 17/03/22 | 09/03/23 | 07/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 71.27 | 96.85 | 93.18 | 96.88 | 97.35 | 94.32 | 91.4 | 94.48 | 93.76 | 91.1 | 89.93 | 91.07 | 93.5 | 94.92 | 95.6 |
EBITDA 1 | 6.862 | 7.583 | 8.616 | 8.797 | 7.71 | 7.144 | 6.819 | 7.04 | 7.309 | 7.505 | 7.133 | 7.683 | 8.7 | 9.433 | 9.65 |
EBIT | -1.116 | 0.136 | -0.208 | 1.726 | 1.253 | -0.385 | - | - | - | - | - | - | - | - | - |
Operating Margin | -1.57% | 0.14% | -0.22% | 1.78% | 1.29% | -0.41% | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | -3.861 | -4.487 | -2.852 | -26.57 | -2.261 | -4.213 | - | - | - | - | - | - | - | - | - |
Net income | -3.928 | -4.447 | -2.762 | -25.13 | -1.782 | -4.68 | - | - | - | - | - | - | - | - | - |
Net margin | -5.51% | -4.59% | -2.96% | -25.94% | -1.83% | -4.96% | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1100 | -0.0700 | -0.0600 | -0.5300 | -0.0400 | -0.1000 | -0.0400 | 0.0300 | -0.0200 | -0.0600 | -0.0250 | -0.0150 | 0.005000 | 0.0150 | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 09/11/21 | 17/03/22 | 11/05/22 | 15/08/22 | 09/11/22 | 09/03/23 | 10/05/23 | 10/08/23 | 08/11/23 | 07/03/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | 56.6 | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | 4.428 x | - | - | - | - | - | - |
Free Cash Flow 1 | - | -1.33 | 1.92 | 8.72 | 18.7 | 16.2 | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | 1.260 | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | 1.56 | 5.35 | 10 | 8.7 | 10 | 8.8 | 7.6 |
Capex / Sales | - | 0.96% | 2.04% | 2.63% | 2.35% | 2.7% | 2.27% | 1.86% |
Announcement Date | 26/03/20 | 10/03/21 | 17/03/22 | 09/03/23 | 07/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.68% | 93.11M | |
-33.55% | 14.97B | |
-26.73% | 11.95B | |
-28.54% | 6.27B | |
+13.49% | 6.36B | |
-10.37% | 6.12B | |
0.00% | 4.75B | |
+64.00% | 4.58B | |
-8.64% | 3.84B | |
-10.56% | 3.51B |
- Stock Market
- Equities
- CRRX Stock
- Financials CareRx Corporation